Kathryn A. Tunstall, Chairman of the Board of Directors since January 2000, has served as one of the Compnay's directors since July 1993 and served as the Company's President and Chief Executive Officer from July 1993 to December 1999. Prior to joining the Company, Ms. Tunstall spent seven years as an executive officer of the Edwards Less Invasive Surgery Division of Baxter International, a division engaged in the research and development, manufacturing and marketing of cardiovascular catheters, serving as President from June 1990 to June 1993 and serving as Vice President and Director of Worldwide Sales and Marketing from November 1986 to June 1990. From 1974 to 1986, Ms. Tunstall held various positions in finance, operations and marketing in two divisions of American Hospital Supply Corporation, including that of Vice President of Marketing of McGaw Laboratories, a pharmaceutical and medical device company. Ms. Tunstall also currently serves as a director and as Compensation Committee Chair of Caliper Lifesciences, a public biotechnology company and is Chairman of the Board of NeoMatrix, a private company involved in breast cancer screening. Ms. Tunstall holds a B.A. in Economics from the University of California and has also completed graduate level studies in Business and Healthcare Administration.

Mark M. Sieczkarek was appointed as the Company's President and Chief Executive Officer and to the Board of Directors in April 2003. Mr. Sieczkarek served as President, Americas, of Bausch and Lomb, Inc. from July 2001 to January 2003, as Corporate Vice President and President—Europe, Middle East and Africa Region from 1999 to 2001 and held positions of increasing responsibility at various divisions of Bausch and Lomb from 1995 to 1999. Prior to joining Bausch and Lomb, Mr. Sieczkarek was Vice President and Chief Financial Officer of KOS Pharmaceuticals from 1993 to 1995. From 1980 to 1993, Mr. Sieczkarek held executive level positions in Finance and Commercial Operations with several Bristol Myers-Squibb subsidiaries and Sanofi Diagnostics Pasteur. Mr. Sieczkarek currently serves on the Board of Directors of Solta, Inc., a public medical device company, where he also participates on both its Audit and Compensation Committees. He is also a board member of the Medical Device Manufacturers Association. Mr. Sieczkarek holds a B.S. in Accounting from the State University of New York at Buffalo and a M.B.A. degree in Finance from Canisius College.

Robert V. Toni was appointed to the Company's Board of Directors in October 2003. Mr. Toni retired in October 2002 from Closure Medical Corporation, where he held the position of President and Chief Executive Officer and served on the Executive Committee for eight years. Previous to Closure Medical, Mr. Toni was General Manager of Iolab Corporation for five years and held a number of senior positions with Coopervision Cilco for seven years with his last position being President. Mr. Toni's earlier career was primarily in financial management for several large companies, including AMF and General Motors where he held the positions of Controller and Accounting Manager, respectively. He holds a B.B.A. from Iona College.

Peter L. Wilson was appointed to the Company's Board of Directors in December 2001 and was appointed as the lead independent director in November 2002. Mr. Wilson currently serves on the board of directors of ArthroCare Corporation. Mr. Wilson was President and Chief Executive Officer of Patient Education Systems from 1995 to 1998. Between 1992 and 1994, Mr. Wilson was an independent consultant in healthcare business development and marketing. From 1972 to 1992, Mr. Wilson worked for Proctor & Gamble / Richardson Vicks, where he held various positions as President of Richardson Vicks, Vice President/General Manager of Proctor & Gamble Vicks Healthcare, President/General Manager of the Vidal Sassoon Division and President/General Manager of the Personal Care Division. Mr. Wilson holds a B.A. from Princeton University and a M.B.A. in Marketing from Columbia University.

Thomas F. Bonadio was appointed to the Company's Board of Directors in September 2003. Mr. Bonadio is the founder and managing partner of The Bonadio Group, an independent provider of accounting, business advisory and financial services in the upstate New York area and a top 100 certified public accounting firm in the United States. He founded this business in 1978, following seven years with Arthur Andersen & Co. Mr. Bonadio is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants. He holds a B.B.A. from St. John Fisher College, and is the past chairman of St. John Fisher College's Board of Trustees.

John L. Bishop was appointed to the Company's Board of Directors in February 2009. Mr. Bishop currently serves on the Biotechnology Industry Organization (BIO) and the BIO Health Section Governing Board. Mr. Bishop is Chief Executive Officer of Cepheid, Inc., a leading molecular diagnostics company. Mr. Bishop joined Cepheid as Chief Executive Officer in 2002. Prior to this, he served as Chief Executive Officer of Vysis, a genomic disease management company from 1996 to March 2002, and as president and a director from 1993 to 2002. From 1991 until November 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. He began his career at American Hospital Supply Company in 1968 and held various management positions of increasing responsibility both in the United States and overseas. Mr. Bishop holds a BS degree from the University of Miami.

Paul A. LaViolette was appointed to the Company's Board of Directors in December 2008. Mr. LaViolette currently serves on the Board of Directors of DJO, Cameron Health, Trans1, Inc. and Direct Flow Medical, Inc. and is a Venture Partner with SV Life Sciences Advisers, LLC. Mr. LaViolette most recently served as Chief Operating Officer of Boston Scientific Corporation until his retirement in June 2008. He joined Boston Scientific in January 1994 and had been COO since 2004. During his 15-year career at Boston Scientific, Mr. LaViolette ran the International, Endosurgery, Interventional Cardiology and Cardiovascular businesses. Prior to joining Boston Scientific, he spent 10 years with C.R. Bard, Inc. Mr. LaViolette holds a B.A. from Fairfield University and an M.B.A from Boston College.